How Does Marburg Virus Enter Cells so Efficiently?
University of Minnesota scientists pinpointed structural features of the Marburg virus entry protein that make it up to 300 times more efficient at infiltrating human cells than Ebola’s. By creating a tightly controlled assay, they showed the protein binds the shared human receptor in a unique orientation with higher affinity and undergoes shape changes that promote fusion. The team also identified a nanobody that can slip past the protein’s protective cap, bind the entry site, and block infection in laboratory models. These findings expose a clear therapeutic vulnerability in one of the deadliest filoviruses.
Psychedelic Medicine Shifts From Stigma to Scientific Momentum
1/6 Excited to join @START_Global this week in Switzerland for a fireside chat on the psychedelic medicine opportunity. As co-founder and former CEO of one of the first psychedelics-focused biotechs, I’ve had a front-row seat to this field’s move from stigma...
China Startup CirCode Gets Clearance for Trial of Circular RNA Therapy
Cir‑Code Bio‑med, a Chinese biotech focused on circular RNA medicines, has secured an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration to commence its first human trial. The therapy targets a rare genetic disorder using a...
Clostridia From Preterm Infants Harness HMOs to Protect Gut
A Nature Microbiology study reveals that specific Clostridia strains isolated from preterm infants can efficiently metabolize human milk oligosaccharides (HMOs). The bacterial conversion produces short‑chain fatty acids and other bioactive metabolites that suppress pathogenic bacteria and enhance intestinal barrier gene...
Silicon Nanotube Arrays Deliver mRNA Into Human Stem Cells While Preserving Pluripotency
A team from Monash and Deakin Universities demonstrated that silicon nanotube arrays can deliver functional mRNA into human induced pluripotent stem cells (hiPSCs) with transfection efficiencies between 55% and 64%. By redesigning nanotube geometry, using low‑molecular‑weight poly‑D‑lysine, and adjusting the...
Electron Microscopy Reveals How Mitochondrial Stress Proteins Remodel to Protect Cells
Researchers at University Medical Center Göttingen employed cryo‑electron tomography to capture near‑atomic structural remodeling of the mitochondrial heat‑shock protein 60 (mHsp60) under proteostatic stress. The protein reconfigures its barrel‑shaped complex, boosting folding activity and preserving mitochondrial function in stressed human...
Biotech Building ‘Molecular Glues’ AI Platform Raises £3.6m
London‑based Ternary Therapeutics announced a £3.6 million seed round to fund its AI‑driven platform for designing molecular glues, a class of drugs that can bind previously "undruggable" proteins. The startup, founded in 2024, merges machine learning, physics‑based molecular modelling and rapid...
STAT+: Structure Therapeutics Reports Significant Weight Loss From Mid-Stage GLP-1 Pill
Structure Therapeutics announced that its daily oral GLP‑1 obesity pill produced an average 16% body‑weight reduction versus placebo after 44 weeks in a Phase 2 trial. The result outperforms Eli Lilly’s orforglipron, which showed about 11% loss over 72 weeks, and rivals...
Structure Therapeutics Reports More Phase 2 Data for Oral GLP-1
Structure Therapeutics released Phase 2 data for its oral GLP‑1 agonist, positioning the candidate as a next‑generation alternative to injectable therapies from Eli Lilly and Novo Nordisk. The trial demonstrated a mean 30% reduction in HbA1c and 70% of participants achieving target...
The Peptide Boom Is Getting Out of Hand
The Atlantic outlines a surge in off‑label and experimental peptide use, noting that Vyleesi—approved for women’s hypoactive sexual desire disorder—is being bought by men through “research use only” listings and online pharmacies. Compounding pharmacies and telehealth firms now market customized...
The Antibacterials of Tomorrow
The blog recaps the 2026 New Antibacterial Discovery and Development conference in Tuscany, where researchers presented emerging strategies against antimicrobial resistance (AMR). Dr. Quave highlighted her lab’s plant‑derived natural products targeting Gardnerella vaginalis, a key cause of bacterial vaginosis. The...
After Novartis Pact, Macrocycle Shop Unnatural Products Gets $45M Series B
Santa Cruz‑based Unnatural Products secured a $45 million Series B round to accelerate its macrocycle drug platform. The financing follows a newly announced partnership with Novartis that will grant the pharma giant early access to the company’s pipeline and a co‑development option...
RevnaBio Secures Triple International Laboratory Accreditation to Expand Precision Medicine and Clinical Research Infrastructure in Africa
RevnaBio received triple accreditation from the American Association for Laboratory Accreditation (A2LA) for ISO 15189, ISO 20387 and ISO/IEC 17043, validating its medical laboratory, biobanking and proficiency‑testing operations. The certifications boost diagnostic quality, enable local molecular testing, and provide a trusted platform for...
Biophytis and LynxKite Expand Alliance to Boost AI-Driven Drug Discovery
Biophytis has broadened its alliance with AI specialist LynxKite to fast‑track longevity drug discovery, launching the MASSIVE project that seeks Mas receptor activators for sarcopenia. Backed by Enterprise Singapore, the partnership will augment Biophytis’ computational platform with LynxKite’s chemoinformatics, advanced...
Bayer Reports the P-III (FIND-CKD) Trial Data on Kerendia in Non-Diabetic Chronic Kidney Disease
Bayer disclosed results from the pivotal Phase III FIND‑CKD trial evaluating Kerendia (finerenone) in more than 1,500 adults with non‑diabetic chronic kidney disease. Patients received 10 mg or 20 mg of Kerendia alongside standard of care and were compared with placebo. The study...
KERENDIA® (Finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
Bayer announced that Kerendia® (finerenone) met its primary endpoint in the Phase III FIND‑CKD trial, showing a statistically significant slowing of eGFR decline versus placebo in non‑diabetic chronic kidney disease patients. The study enrolled over 1,500 participants and represents the fifth...
IGFBP7 Secreted by Senescent Cells Suppresses the Benefits of Exercise
Researchers identified insulin‑like growth factor binding protein‑7 (IGFBP7) as a circulating factor that limits exercise adaptation in older adults. Plasma proteomics from a year‑long high‑intensity interval training trial showed higher IGFBP7 levels predicted smaller fitness gains. In mice, genetic deletion...
Exploring Light and Life: Nanophotonics and AI for Molecular Sequencing and Single-Cell Phenotyping
Prof. Dionne introduced VINPix, a silicon‑photonic resonator platform with ultra‑high Q factors and sub‑wavelength mode volumes, capable of housing over 10 million devices per square centimeter. Coupled with acoustic bioprinting and artificial intelligence, the system promises simultaneous detection of genes, proteins,...
J&J Reports Positive Data for Erda-iDRS in Bladder Cancer
Johnson & Johnson announced encouraging Phase I data for its intravesical drug‑releasing system Erda‑iDRS in non‑muscle‑invasive bladder cancer (NMIBC) with FGFR alterations. The trial met its primary safety endpoint and delivered an 89% complete response rate in intermediate‑risk patients, with responses...
Spotlight Pathology Secures £1.4 Million Seed Investment for AI Blood Cancer Diagnostics
Liverpool‑based Spotlight Pathology has closed a £1.4 million seed round to accelerate its AI‑driven blood cancer diagnostic platform. The round was co‑led by the UK Innovation and Science Seed Fund and the Liverpool City Region Seed Fund, earmarked for product development,...
Roche Receives CE Mark for Its Elecsys ApoE4 Test to Support Blood-Based Alzheimer’s Biomarker Testing
Roche has secured CE Mark approval for its Elecsys ApoE4 in‑vitro diagnostic immunoassay, a blood‑based test that detects the ApoE4 gene variant linked to Alzheimer’s disease. In a validation study of 607 patients with cognitive complaints, the assay achieved 100%...
Effects of Mycoplasma Gallisepticum Infection on the Microbial Community Structure and Function in the Oviduct Magnum of Laying Hens
A preprint investigating Mycoplasma gallisepticum infection in Roman Gray laying hens reveals that infected birds host more operational taxonomic units (473 vs. 356) and a microbiome dominated by Mycoplasmatota. Alpha‑diversity metrics remained unchanged, but beta‑diversity analyses showed a highly significant community restructuring...
Cell Painting Images Predict Cellular Age Without Methylation
A model that predicts cellular age from Cell Painting microscopy images alone. No DNA methylation needed. The model captures morphological aging hallmarks across nuclear and cytoplasmic compartments, correlates with chronological age AND epigenetic clocks. The promise: screen for rejuvenation compounds...
Single‑cell Methylation Reveals Age
Epigenetic aging happens at different rates in individual cells within the same tissue. Using single-cell DNA methylation analysis, Hagit Masika, Tommy Kaplan, Howard Cedar, and colleagues show polycomb CpG island methylation creates 'young' vs 'old' cell subpopulations even at fixed...
Graphene Oxide Quantum Dots Enable Biosensing of Depression Biomarkers
University of Delhi researchers have introduced an eco‑friendly method to synthesize graphene oxide quantum dots (GO QDs) using citric acid, producing uniform 23.4 nm particles with a negative surface charge. The GO QDs enable dual‑mode biosensing—optical fluorescence and electrochemical detection—of the...
Structure's Obesity Pill Shows Phase 2 Weight‑Loss Promise
Pretty impressive data from $gpcr, which remains my favorite ticker. Structure's obesity pill shows weight loss promise in Phase 2 trial https://t.co/T0JU2UuftY
Aging Can Be Treated, Says Harvard Scientist Sinclair
The scientist trying to reverse aging in humans: David Sinclair. This Harvard researcher spent 30 years studying aging—and now says it's a treatable medical condition. He reveals how on the World Governments Summit: https://t.co/VRgBFtCiRW
Inter‐Crystal Spacing of Implantable Polymeric Surfaces as a Key Suppressor of Microbial Adhesion.
The researchers demonstrated that repeated shape‑memory polymer (SMP) recovery aligns surface crystals and compresses amorphous gaps, dramatically reducing bacterial adhesion. In vitro assays with Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus showed progressive detachment as programming cycles increased. An SMP...
EU Approves Imfinzi‑chemo Combo for Gastric Cancers
#AZN Imfinzi (durvalumab) combined with 'standard-of-care' Chemotherapy has been approved in the EU for treating Adults with forms of Gastric and Gastroesophageal Junction Cancers, following the MATTERHORN Phase III trial.
12-Year AI Drug Expert Unfamiliar
In my 12 years in AI drug discovery, I have not heard of this company, have you? Original Bloomberg post by @AmberTongPW https://t.co/9C4LY1c5Um and full text by China Dailly https://t.co/z3xG5Y5HBI https://t.co/fnddeGtdEW
Viatris Settles Lawsuit Over Use of Woman’s ‘Immortal’ Cells to Power Drug Research
Viatris agreed to dismiss the Henrietta Lacks estate lawsuit with prejudice, ending claims that the company used HeLa cells without permission in its herpes drug Denavir and depression treatment Mylan‑Mirtazapine. The settlement details were kept confidential. This resolution follows similar...
#384 – Special Episode — Obicetrapib: The CETP Inhibitor with Cardiovascular Benefits and Potential Alzheimer’s Prevention
Obicetrapib, a next‑generation CETP inhibitor, has demonstrated potent LDL‑C, apoB, and Lp(a) reductions in a large phase III lipid trial. A pre‑specified biomarker sub‑study reported a marked attenuation of p‑tau217 progression, especially among APOE4/4 carriers, hinting at a potential Alzheimer’s‑related benefit....
#384 - Special Episode — Obicetrapib: The CETP Inhibitor with Cardiovascular Benefits and Potential Alzheimer's Prevention
In this special episode, host Peter Atiyah dives deep into obicetrapib, a CETP inhibitor that lowers LDL‑C and ApoB while raising HDL‑C, and examines its renewed promise in cardiovascular disease and potential Alzheimer’s prevention, especially for APOE‑E4 carriers. He outlines...
Denali’s Hunter Syndrome Candidate in the Spotlight After REGENXBIO Rejection
REGENXBIO's gene therapy RGX‑121 for Hunter syndrome received an FDA Complete Response Letter, with the agency flagging patient‑eligibility definitions, natural‑history control comparability, and the surrogate endpoint as problematic. The rejection redirects focus to Denali Therapeutics, whose enzyme‑replacement candidate tividenofusp alfa...
Aging Driven by DNA Instability and Mitochondrial Decline
So great to see the OG work that helped spark the longevity revolution taken to the next level: New paper confirms two main causes of aging: 1. DNA instability -> epigenetic noise 2. Mitochondrial decline ...independently causing failure of the cell Is this relevant to...
Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-Acting Semaglutide
Samsung Bioepis and its sister firm Epis NexLab have signed a research collaboration and exclusive license agreement with G2GBIO to develop a long‑acting semaglutide formulation using G2GBIO’s proprietary microsphere technology. The deal grants Samsung Bioepis full rights to the semaglutide...
Vitamin B2 Pathway Identified as Potential Target for Cancer Therapy
A CRISPR‑Cas9 screen revealed that riboflavin (vitamin B2) sustains the ferroptosis suppressor protein FSP1, shielding cancer cells from iron‑driven lipid peroxidation. Depleting vitamin B2 destabilizes FSP1 and renders tumor cells highly susceptible to ferroptosis. The researchers demonstrated that roseoflavin, a bacterial analog...
Australia OKs Coin-Sized Sensor for Hydrocephalus Management
Australian regulators have approved M.scio, a coin‑sized, fully implanted intracranial pressure sensor developed by Germany’s Miethke and distributed by B. Braun. The Class III device provides continuous, telemetric ICP data for up to four years and is available in Flat and Dome...
Graph AI Accelerates Longevity Drug Discovery in New Alliance
Solve Aging: Biophytis and LynxKite are expanding their alliance to use graph-based AI to speed discovery of new longevity drugs, aiming to map complex aging biology and surface novel targets for age-related disease. The “AI x longevity” stack is quietly...
Summit Midstream Corp (SMC) Q4 2025 Earnings Call Transcript
Summit Therapeutics reported a cash balance of $713 million and zero debt at year‑end, while GAAP operating expenses fell to $225 million. The FDA accepted its Biologics License Application for ivonesumab in EGFR‑mutant non‑small cell lung cancer, setting a PDUFA action date...
Singapore: AI, Genomics to Advance Precision Cancer Diagnostics
Singapore’s Agency for Science, Technology and Research has teamed with a precision‑oncology firm and the National Cancer Centre to launch UNITED 2.0, a SG$6 million three‑year project aimed at a clinical‑grade cancer profiling test. The new platform will replace the gene‑panel approach...
Hong Kong: Cross-Border Corridor to Drive Medical Innovation
The University of Hong Kong and Suzhou Industrial Park have signed a memorandum of understanding to launch the HKU‑Suzhou Innovation Corridor, a cross‑border platform for medical technology development. The corridor will link HKU’s research expertise with Suzhou’s clinical and biotech...
Monocyte Immune Shifts in HIV Patients on Injectable Therapy
Researchers published a longitudinal study showing that people living with HIV who switch from daily oral antiretrovirals to the long‑acting injectable combo cabotegravir‑rilpivirine experience an early, transient rise in monocyte activation followed by a sustained decline below baseline levels. Flow...
Approve Longevity Drugs for Disease First, Then Expand to Aging
The only sustainable path to development of longevity therapeutics is to get the potential longevity drug approved for a disease, then go for indication expansion and study it in the context of aging at different doses and regimens. To be...
Open‑source Hermes Agent for mRNA Vaccine Design
Has anyone built full open source tooling for Hermes Agent @NousResearch for Bioinformatics (mRNA vaccine design is the target)? It'll need new agent skills too. Would you use it if I built it? I have a few hours left to...
AI Beats FDA, Prompting DIY Drug Use
AI's capabilities have outpaced the FDA's capabilities to regulate it There are literal cures that can be designed and synthesized but have no way to reach the market due to regulatory/ethics blocks People will, like with Peptides, start dosing themselves & their...
Low‑Cost Vaccines Fight Pseudoscience, Yet Remain Unaccepted
Please @X I make low cost vaccines to help humanity and debunk pseudoscience. This is unacceptable
GLP‑1 Drugs: Promising yet Unproven Healthspan Extension
GLP-1 drugs for extending healthspan? Intriguing but we're a long way off from evidence Discussed at length in Super Agers as a candidate drug beyond lifestyle + factors @TheEconomist gift link https://t.co/A2dpfcnApF https://t.co/3gY8iACeGs
Variant Bio Hunts Rare Traits For
From a tiny idea in our Lux office to deal after deal... ...@VariantBio finding outlier people, with outlier traits, in outlier parts of the world to make outlier drugs. organ by organ ... https://t.co/I5fK8nzZb4
Chemical Tools Uncover Active Microbes in Complex Ecosystems
🔎 Chemical biology tools reveal which microbes are truly working behind the scenes 🔗 https://t.co/oFvPY4Uz95 🌐 #INPST #Biotech #CRBIOTECH https://t.co/tGA5P30yM1